Figure 5.
Observed and predicted sulfonylurea prescriptions as a proportion of all prescriptions for non-insulin antihyperglycemic medications among state Medicaid programs that did (A) and did not (B) provide coverage for rosiglitazone, 2006–2009, along with the prescription rates that would have been expected had the rosiglitazone safety warnings not been issued.
Source: Authors’ analyses based on IMS HEALTH Xponent™ database.